PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ) Investor Relations Material

Overview

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company that is focused on finding novel therapies for cardiovascular and cardiopulmonary diseases. Its pipeline includes bentracimab, a reversal agent for ticagrelor, PB1046 for pulmonary arterial hypertension and hospitalized COVID-19 patients and PB6440 for resistant hypertension. The company utilizes its proprietary elastin-like polypeptide technology platform to develop therapies with better pharmacokinetics and less-frequent dosing, which leads to both internal and partnership drug-development opportunities.

Annual Reports

Frequently Asked Questions

What is PhaseBio Pharmaceuticals, Inc.'s ticker?

PhaseBio Pharmaceuticals, Inc.'s ticker is PHAS

What exchange is PhaseBio Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are PhaseBio Pharmaceuticals, Inc.'s headquarters?

They are based in Malvern, Pennsylvania

How many employees does PhaseBio Pharmaceuticals, Inc. have?

There are 11-50 employees working at PhaseBio Pharmaceuticals, Inc.

What is PhaseBio Pharmaceuticals, Inc.'s website?

It is https://phasebio.com/

What type of sector is PhaseBio Pharmaceuticals, Inc.?

PhaseBio Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is PhaseBio Pharmaceuticals, Inc.?

PhaseBio Pharmaceuticals, Inc. is in the Biotechnology industry

Who are PhaseBio Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are PhaseBio Pharmaceuticals, Inc.'s industry peers:

- Axsome Therapeutics

- Motus GI

- Urovant Sciences Ltd.

- TFF Pharmaceuticals

- Celldex Therapeutics Inc.